Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety,
tolerability and efficacy of sotorasib in combination with chemotherapy for patients with
advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line
treatment. There will be a safety lead in to determine the safety and tolerability of the
sotorasib in combination with standard chemotherapy. A Simon two-stage design will be
employed to evaluate the efficacy of sotorasib in combination with standard of care second
line chemotherapy.